CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma

Summary Despite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker‐directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemetostat in EZH2‐mutant FL. Here we examined whether gene mutatio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology Jg. 205; H. 5; S. 1804 - 1809
Hauptverfasser:	Kumar, Emil Arjun, Korfi, Koorosh, Bewicke‐Copley, Findlay, Close, Karina, Heward, James, Witzig, Thomas, Leukam, Michael, Ansell, Stephen, Scott, Jessica, Clear, Andrew, Efeyan, Alejo, Green, Michael, Siebert, Reiner, Peck, Barrie, Calaminici, Maria, Wang, Jun, Smith, Sonali, Novak, Anne, Fitzgibbon, Jude, Okosun, Jessica
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Blackwell Publishing Ltd 01.11.2024
Schlagworte:	Aged Biomarkers Biopsy Clinical trials CREB-Binding Protein - genetics CREBBP Everolimus - therapeutic use Female follicular lymphoma genetics Histone acetyltransferase Humans Lymphoma Lymphoma, Follicular - drug therapy Lymphoma, Follicular - genetics Male Middle Aged mTOR inhibition MTOR Inhibitors - pharmacology MTOR Inhibitors - therapeutic use Mutation mutation analysis Point mutation Protein Domains Recurrence Sirolimus - analogs & derivatives TOR protein TOR Serine-Threonine Kinases - antagonists & inhibitors mTOR inhibition CREBBP genetics follicular lymphoma mutation analysis
ISSN:	0007-1048, 1365-2141, 1365-2141
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!